100+ peptides at a glance — common vial sizes, reconstitution ratios, target research doses, protocol windows, and links to the primary literature. Click any row to open the calculator with those numbers pre-loaded.
| Peptide | Category | Common vial | BAC water | Concentration | Research dose | → Units (U-100) | Protocol window | Cites | |
|---|---|---|---|---|---|---|---|---|---|
BPC-157 Pentadecapeptide |
Recovery | 5 mg | 2 mL | 2.5 mg/mL | 200–500 mcg 1–2× daily | 10 units (250 mcg) | 4–6 wks on / 2–4 off | 42 | |
TB-500 Thymosin β4 fragment |
Recovery | 10 mg | 3 mL | 3.3 mg/mL | 2–2.5 mg 1–2× weekly | 60 units (2 mg) | 4–6 wks loading, then maint. | 28 | |
KPV Lys-Pro-Val tripeptide |
Recovery | 10 mg | 2 mL | 5 mg/mL | 200–500 mcg daily | 4 units (200 mcg) | Continuous, monitor | 14 | |
LL-37 Cathelicidin antimicrobial |
Recovery | 5 mg | 2 mL | 2.5 mg/mL | 100–500 mcg daily | 4 units (100 mcg) | 2 wks on / 2 off | 19 | |
Thymosin Alpha-1 28-aa immune peptide |
Immune | 5 mg | 2 mL | 2.5 mg/mL | 1.6 mg 2× weekly | 64 units (1.6 mg) | Continuous, physician-guided | 23 | |
Semaglutide GLP-1 receptor agonist |
Metabolic | 5 mg | 2 mL | 2.5 mg/mL | 0.25 mg → 2.4 mg weekly (titrate) | 10 units (0.25 mg start) | 4-wk titration then maint. | 45 | |
Tirzepatide GLP-1 / GIP dual |
Metabolic | 10 mg | 4 mL | 2.5 mg/mL | 2.5 mg → 15 mg weekly (titrate) | 100 units (2.5 mg start) | 4-wk titration steps | 31 | |
Retatrutide GLP-1 / GIP / glucagon |
Metabolic | 10 mg | 3 mL | 3.3 mg/mL | 2 mg → 12 mg weekly (titrate) | 60 units (2 mg start) | Phase 3 trial protocol | 18 | |
AOD-9604 HGH fragment 176-191 |
Metabolic | 5 mg | 2 mL | 2.5 mg/mL | 250–500 mcg daily | 10 units (250 mcg) | 4–8 wks | 11 | |
Cagrilintide Amylin analog |
Metabolic | 5 mg | 2 mL | 2.5 mg/mL | 0.3 mg → 2.4 mg weekly | 12 units (0.3 mg start) | 16-wk titration | 9 | |
CJC-1295 (no DAC) GHRH analog · short-acting |
GH sec. | 5 mg | 2 mL | 2.5 mg/mL | 100 mcg 1–3× daily | 4 units (100 mcg) | 5 days on / 2 off, 8-wk cycles | 16 | |
Ipamorelin Selective ghrelin agonist |
GH sec. | 5 mg | 2 mL | 2.5 mg/mL | 100–300 mcg 1–3× daily | 8 units (200 mcg) | 5 days on / 2 off | 21 | |
Sermorelin GHRH 1-29 bioidentical |
GH sec. | 5 mg | 2 mL | 2.5 mg/mL | 200–300 mcg before sleep | 8 units (200 mcg) | Continuous, monitor IGF-1 | 27 | |
Tesamorelin GHRH analog · long-acting |
GH sec. | 10 mg | 2 mL | 5 mg/mL | 1–2 mg daily | 20 units (1 mg) | 12–26 wks | 14 | |
GHRP-6 Ghrelin agonist |
GH sec. | 5 mg | 2 mL | 2.5 mg/mL | 100–150 mcg 1–3× daily | 4 units (100 mcg) | 5 days on / 2 off | 12 | |
Epitalon Ala-Glu-Asp-Gly |
Longevity | 10 mg | 2 mL | 5 mg/mL | 5–10 mg daily | 100 units (5 mg) | 10-day protocol, 2×/yr | 17 | |
NAD+ Coenzyme |
Longevity | 500 mg | 10 mL | 50 mg/mL | 50–100 mg 3× weekly | 100 units (50 mg) | 4–8 wks loading | 22 | |
SS-31 (Elamipretide) Mito-targeted tetrapeptide |
Longevity | 10 mg | 2 mL | 5 mg/mL | 1–5 mg daily | 20 units (1 mg) | Continuous in trials | 15 | |
MOTS-C Mitochondrial-derived |
Longevity | 10 mg | 2 mL | 5 mg/mL | 5–10 mg 2× weekly | 100 units (5 mg) | 6–12 wks | 10 | |
Semax ACTH fragment analog |
Cognitive | 10 mg | 1 mL | 10 mg/mL | 200–600 mcg intranasal daily | Intranasal spray | 2–4 wks on / 2 off | 13 | |
Selank Tuftsin analog |
Cognitive | 10 mg | 1 mL | 10 mg/mL | 250–500 mcg intranasal daily | Intranasal spray | 2–3 wks on / 1 off | 11 | |
DSIP Delta sleep-inducing |
Cognitive | 5 mg | 2 mL | 2.5 mg/mL | 100–500 mcg before sleep | 4 units (100 mcg) | 2–4 wks | 8 | |
GHK-Cu Copper-binding tripeptide |
Skin | 50 mg | 5 mL | 10 mg/mL | 1–3 mg topical or subQ | 10 units (1 mg) | Ongoing / topical | 33 | |
Melanotan II α-MSH analog |
Skin | 10 mg | 2 mL | 5 mg/mL | 250 mcg loading → 500 mcg maint. | 5 units (250 mcg) | 2-wk loading, then 2×/wk | 9 | |
PT-141 Bremelanotide · MC4 agonist |
Metabolic | 10 mg | 2 mL | 5 mg/mL | 1–1.75 mg as-needed | 20 units (1 mg) | PRN, ≤8×/month | 14 | |
Oxytocin Neurohypophyseal nonapeptide |
Cognitive | 5 mg | 2 mL | 2.5 mg/mL | 10–40 IU intranasal | Intranasal spray | PRN | 36 |